CV Sciences, Inc.
Close on Oct 19, 2026
- Market cap
- $2.30M
- P/E (TTM)
- –
- Dividend yield
- –
About CV Sciences
Pharmaceutical Preparations, SIC 2834
CV Sciences, Inc. is a consumer wellness company that develops, manufactures, and markets herbal supplements, cannabidiol (CBD) products, and plant-based foods. Its offerings include hemp extracts, cannabinoid-free supplements, and shelf-stable plant-based protein foods marketed under brand names such as +PlusCBD, +PlusHLTH, Cultured Foods, and Lunar Fox. The company serves individual consumers, retailers, wholesalers, and pet owners, while also operating a business-to-business contract manufacturing service that provides custom softgel and tincture encapsulation for clients in the supplement and nutrition industry.
The company operates primary facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland, with its corporate headquarters located in San Diego. Its hemp-based products are distributed across North America through approximately 2,500 brick-and-mortar retail stores and e-commerce platforms. Its plant-based food products are primarily distributed across European retail markets through regional distributors and to select retailers in the United States.
Summary of the business section of CV Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CV Sciences, Inc.
- Founded
- 2010
- Headquarters
- San Diego, CA
- Address
- 9530 Padgett Street, Suite 107 92126
- Phone
- (866) 290-2157
- Website
- cvsciences.com
- Employees
- 44, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- HASKELL & WHITE LLP, Irvine, California
Stock & identifiers
- Ticker
- CVSI
- Exchange
- OTC
- Shares outstanding
- 226M, Aug 11, 2026
- Public float
- $7.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1510964
- CUSIP
- 126654102
- ISIN
- US1266541028
- LEI
- 549300CTTCLKOE31VK58
- EIN
- 80-0944970
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joseph D. Dowling | Chief Executive Officer, Director | 15,000 |
| Joerg Grasser | Chief Financial Officer | 15,000 |
| James Michael Corroon Jr. | Director | 1,000 |
| William McCorkle | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Dowling | $419.00K | $423.10K | $307.99K | – | – |
| FY2024 Mr. Dowling | $457.67K | $241.26K | $343.32K | $100 | – |
| FY2023 Mr. Dowling | $403.15K | $313.97K | $273.04K | $133 | – |
| FY2022 Mr. Dowling | $298.98K | $245.29K | $210.47K | $25 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 44 employees, which included 36 full-time and 1 part-time employee in the U.S.”
Corporate history
Events identified from SEC filings